These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 19156897

  • 1. A critical appraisal of the Janus carbostent.
    Kornowski R.
    Catheter Cardiovasc Interv; 2009 Feb 01; 73(2):249-50. PubMed ID: 19156897
    [No Abstract] [Full Text] [Related]

  • 2. Real world safety and efficacy of the Janus Tacrolimus-Eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Eluting STent (TEST) registry.
    Tamburino C, Di Salvo ME, Capodanno D, Capranzano P, Parisi R, Mirabella F, Scardaci F, Ussia G, Galassi AR, Fiscella D, Mehran R, Dangas G.
    Catheter Cardiovasc Interv; 2009 Feb 01; 73(2):243-8. PubMed ID: 19156896
    [Abstract] [Full Text] [Related]

  • 3. Angiographic restenosis and clinical recurrence after sirolimus- and paclitaxel-eluting stent implantation.
    Vlaar PJ, Zijlstra F.
    JACC Cardiovasc Interv; 2009 Aug 01; 2(8):776-8. PubMed ID: 19695547
    [No Abstract] [Full Text] [Related]

  • 4. Gender medicine and drug eluting coronary stents.
    Kornowski R.
    Catheter Cardiovasc Interv; 2010 Nov 15; 76(6):814-6. PubMed ID: 21104730
    [No Abstract] [Full Text] [Related]

  • 5. Better results with the new generation bare metal stents.
    Vik-Mo H.
    Scand Cardiovasc J; 2009 Apr 15; 43(2):84-6. PubMed ID: 19117238
    [No Abstract] [Full Text] [Related]

  • 6. A generation 2.5 drug-eluting stent?
    Ellis SG.
    JACC Cardiovasc Interv; 2009 Oct 15; 2(10):986-8. PubMed ID: 19850259
    [No Abstract] [Full Text] [Related]

  • 7. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2.
    Chevalier B, Silber S, Park SJ, Garcia E, Schuler G, Suryapranata H, Koolen J, Hauptmann KE, Wijns W, Morice MC, Carrie D, van Es GA, Nagai H, Detiege D, Paunovic D, Serruys PW, NOBORI 1 Clinical Investigators.
    Circ Cardiovasc Interv; 2009 Jun 15; 2(3):188-95. PubMed ID: 20031715
    [Abstract] [Full Text] [Related]

  • 8. Stent strut fracture: seeing is believing.
    Carter AJ.
    Catheter Cardiovasc Interv; 2008 Apr 01; 71(5):619-20. PubMed ID: 18360854
    [No Abstract] [Full Text] [Related]

  • 9. Do we really understand pimecrolimus?
    Vorpahl M, Finn AV, Nakano M, Virmani R.
    JACC Cardiovasc Interv; 2009 Oct 01; 2(10):1025-7. PubMed ID: 19850265
    [No Abstract] [Full Text] [Related]

  • 10. High glycemic stenting menu.
    Hillegass WB.
    Catheter Cardiovasc Interv; 2010 Dec 01; 76(7):934-5. PubMed ID: 21108370
    [No Abstract] [Full Text] [Related]

  • 11. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial.
    Lemos PA, Moulin B, Perin MA, Oliveira LA, Arruda JA, Lima VC, Lima AA, Caramori PR, Medeiros CR, Barbosa MR, Brito FS, Ribeiro EE, Martinez EE, PAINT trial investigators.
    Catheter Cardiovasc Interv; 2009 Nov 01; 74(5):665-73. PubMed ID: 19670303
    [Abstract] [Full Text] [Related]

  • 12. Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: 1-year results from the TAXUS ATLAS program.
    Turco MA, Ormiston JA, Popma JJ, Hall JJ, Mann T, Cannon LA, Webster MW, Mishkel GJ, O'Shaughnessy CD, McGarry TF, Mandinov L, Dawkins KD, Baim DS.
    JACC Cardiovasc Interv; 2008 Dec 01; 1(6):699-709. PubMed ID: 19463387
    [Abstract] [Full Text] [Related]

  • 13. If I've heard it once, I've heard it (not yet) a hundred times.
    Butman SM.
    Catheter Cardiovasc Interv; 2011 Mar 01; 77(4):502. PubMed ID: 21351224
    [No Abstract] [Full Text] [Related]

  • 14. Feasibility, safety, and efficacy of a novel polymeric pimecrolimus-eluting stent: traditional pre-clinical safety end points failed to predict 6-month clinical angiographic results.
    Ormiston JA, Webster MW, Schwartz RS, Gladding P, Stewart JT, Kay IP, Ruygrok PN, Hatrick R.
    JACC Cardiovasc Interv; 2009 Oct 01; 2(10):1017-24. PubMed ID: 19850264
    [Abstract] [Full Text] [Related]

  • 15. Another small step for small vessels.
    Morrison DA.
    Catheter Cardiovasc Interv; 2010 Jul 01; 76(1):67-9. PubMed ID: 20578195
    [No Abstract] [Full Text] [Related]

  • 16. My stent is better than your stent...Or is it?
    Bates ER, Menees DS.
    JACC Cardiovasc Interv; 2011 May 01; 4(5):551-3. PubMed ID: 21596328
    [No Abstract] [Full Text] [Related]

  • 17. Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation.
    Herdeg C, Göhring-Frischholz K, Haase KK, Geisler T, Zürn C, Hartmann U, Wöhrle J, Nusser T, Dippon J, May AE, Gawaz M.
    Circ Cardiovasc Interv; 2009 Aug 01; 2(4):294-301. PubMed ID: 20031731
    [Abstract] [Full Text] [Related]

  • 18. The "mini-crush" technique for managing bifurcation lesions.
    Kornowski R.
    Catheter Cardiovasc Interv; 2009 Jul 01; 74(1):85-7. PubMed ID: 19530202
    [No Abstract] [Full Text] [Related]

  • 19. The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of "oculostenotic" reintervention in patients with intermediate lesions.
    Uchida T, Popma J, Stone GW, Ellis SG, Turco MA, Ormiston JA, Muramatsu T, Nakamura M, Nanto S, Yokoi H, Baim DS.
    JACC Cardiovasc Interv; 2010 Apr 01; 3(4):403-11. PubMed ID: 20398868
    [Abstract] [Full Text] [Related]

  • 20. Treating the left main bifurcation lesion: the "three stent solution".
    Uretsky BF.
    Catheter Cardiovasc Interv; 2009 Jan 01; 73(1):42-3. PubMed ID: 19089935
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.